Read more
Traditionelle und brandneue Strategien für die Entwicklung von Analogwirkstoffen stehen im Mittelpunkt dieses Bandes, der seinen Vorgänger deutlich erweitert: Neun Klassen von Analoga kommen hinzu, dazu acht Fallstudien aus einer breiten Palette von Substanzklassen und therapeutischen Einsatzgebieten.
List of contents
PART I GENERAL ASPECTSOptimizing Drug Therapy by AnaloguesStandalone DrugsApplication of Molecular Modeling in Analogue-Based Drug DiscoveryIssues for the Patenting of AnaloguesPART II ANALOGUE CLASSESDipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 DiabetesPhosphodiesterase 5 Inhibitors to Treat Erectile DysfunctionRifamycins, Antibacterial Antibiotics and Their New ApplicationsMonoterpenoid Indole Alkaloids, CNS Anticancer DrugsAnthracyclines, Optimizing Anticancer AnaloguesPaclitaxel and Epothilone Analogues, Anticancer DrugsSelective Serotonin Reuptake Inhibitors for the Treatment of DepressionMuscarinic Receptor Antagonists in the Treatment of COPDbeta-Adrenoceptor Agonists and AsthmaPART III CASE HISTORIESLiraglutide, a GLP-1 Analogue to Treat DiabetesEplerenone: Selective Aldosterone AntagonistClevudine, to Treat Hepatitis B Viral InfectionRilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIVLapatinib, an Anticancer Kinase InhibitorDasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous LeukemiaVenlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder
About the author
János Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest.
C. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co inventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is co inventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
Summary
Traditionelle und brandneue Strategien für die Entwicklung von Analogwirkstoffen stehen im Mittelpunkt dieses Bandes, der seinen Vorgänger deutlich erweitert: Neun Klassen von Analoga kommen hinzu, dazu acht Fallstudien aus einer breiten Palette von Substanzklassen und therapeutischen Einsatzgebieten.
Report
"Analogue-Based Drug Discovery II is a companion book to the first volume ... This volume provides an excellent
overview of several biological targets, compound classes, and illustrations of problem solving in medicinal chemistry for chemists in drug discovery who are beginning to establish their careers" (ChemMedChem, 1 January 2012)
